Evidence map›Paper›PMID 38509244›Full record

ReviewNature reviews. Cardiology2024

Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease.

Azita H Talasaz, Parham Sadeghipour, Luis Ortega-Paz, Hessam Kakavand, Maryam Aghakouchakzadeh, Craig Beavers, John Fanikos, John W Eikelboom, Deborah M Siegal, Manuel Monreal and 26 more

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05024864 (HELicobacter Pylori Screening to Prevent Gastrointestinal Bleeding in Patients With Acute Myocardial Infarction), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05024864 naactive not recruitingnot on this map

HELicobacter Pylori Screening to Prevent Gastrointestinal Bleeding in Patients With Acute Myocardial Infarction (HELP-MI SWEDEHEART)

TypeinterventionalSponsorKarolinska InstitutetRan2021 to 2030Enrolled20,000ConditionsMyocardial Infarction, Helicobacter Pylori Infection, GastroIntestinal Bleeding, Cardiovascular DiseasesArmsUrea breath test (UBT)
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. ShSPI Inhibits Thrombosis Formation and Ischemic Stroke In Vivo.International journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

36 authors.

Azita H TalasazArnold & Marie Schwartz College of Pharmacy and Health Sciences, Department of Pharmacy Practice, Long Island University, New York, NY, USA.ORCID 0000-0003-1839-3685
Parham SadeghipourRajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.ORCID 0000-0001-9602-0513
Luis Ortega-PazDivision of Cardiology, University of Florida College of Medicine, Jacksonville, FL, USA.
Hessam KakavandRajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
Maryam AghakouchakzadehTehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Craig BeaversUniversity of Kentucky College of Pharmacy, Lexington, KY, USA.
John FanikosDepartment of Pharmacy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
John W EikelboomPopulation Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada.ORCID 0000-0003-4126-1285
Deborah M SiegalDivision of Hematology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.ORCID 0000-0003-3806-3245
Manuel MonrealDepartment of Internal Medicine, Hospital Universitari Germans Trials i Pujol, Universidad Católica San Antonio de Murcia, Barcelona, Spain.ORCID 0000-0002-0494-0767
David JimenezRespiratory Department, Hospital Ramón y Cajal and Medicine Department, Universidad de Alcalá (IRYCIS), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, ISCIII, Madrid, Spain.ORCID 0000-0002-4571-7721
Muthiah VaduganathanCardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Lana A CastellucciDepartment of Medicine, Ottawa Hospital Research Institute at the University of Ottawa, Ottawa, Ontario, Canada.
Adam CukerDepartment of Medicine and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Geoffrey D BarnesFrankel Cardiovascular Center, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-6532-8440
Jean M ConnorsHematology Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Eric A SecemskyDivision of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Benjamin W Van TassellDepartment of Pharmacotherapy and Outcome Sciences, Virginia Commonwealth University, Richmond, VA, USA.
Raffaele De CaterinaCardiology Division, Pisa University Hospital, Pisa, Italy.ORCID 0000-0003-1637-574X
Jacob E KurlanderDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Ali AminianBariatric and Metabolic Institute, Department of General Surgery, Cleveland Clinic, Cleveland, OH, USA.
Gregory PiazzaCardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Samuel Z GoldhaberCardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Lisa MooresF. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Saskia MiddeldorpDepartment of Internal Medicine, Radboud Institute of Health Sciences (RIHS), Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0000-0002-1006-6420
Ajay J KirtaneCardiovascular Research Foundation, New York, NY, USA.
Mitchell S V ElkindDepartment of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Dominick J AngiolilloDivision of Cardiology, University of Florida College of Medicine, Jacksonville, FL, USA.ORCID 0000-0001-8451-2131
Stavros KonstantinidesCenter for Thrombosis and Hemostasis, Johannes Gutenberg, University of Mainz, Mainz, Germany.
Gregory Y H LipLiverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, UK.
Gregg W StoneMount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-3416-8210
Mary CushmanUniversity of Vermont Medical Center, Burlington, VT, USA.
Harlan M KrumholzYale New Haven Hospital/Yale Center for Outcomes Research and Evaluation, New Haven, CT, USA.ORCID 0000-0003-2046-127X
Roxana MehranMount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-5546-262X
Deepak L BhattMount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-1278-6245
Behnood BikdeliCardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. bbikdeli@bwh.harvard.edu.

Funding

Classification and Prognostication in Pulmonary Thromboembolism Using Computed Tomography Image AnalyticsR01HL164717 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Farbod Nicholas Rahaghi · 2022 to 2026
$3.6M
Shared Decision-Making to Improve the Health Status of Patients with Claudication: Developing and Implementing Strategies to Individualize Treatment DecisionsK23HL150290 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SECEMSKY, ERIC ALEXANDER · 2020 to 2024
$851k
NHLBI NIH HHS K23 HL150290NHLBI NIH HHS R01 HL164717
6 · The paper itself

Abstract

Balancing the safety and efficacy of antithrombotic agents in patients with gastrointestinal disorders is challenging because of the potential for interference with the absorption of antithrombotic drugs and for an increased risk of bleeding. In this Review, we address considerations for enteral antithrombotic therapy in patients with cardiovascular disease and gastrointestinal comorbidities. For those with gastrointestinal bleeding (GIB), we summarize a general scheme for risk stratification and clinical evidence on risk reduction approaches, such as limiting the use of concomitant medications that increase the risk of GIB and the potential utility of gastrointestinal protection strategies (such as proton pump inhibitors or histamine type 2 receptor antagonists). Furthermore, we summarize the best available evidence and potential gaps in our knowledge on tailoring antithrombotic therapy in patients with active or recent GIB and in those at high risk of GIB but without active or recent GIB. Finally, we review the recommendations provided by major medical societies, highlighting the crucial role of teamwork and multidisciplinary discussions to customize the antithrombotic regimen in patients with coexisting cardiovascular and gastrointestinal diseases.

Indexed as

Cardiovascular DiseasesFibrinolytic AgentsGastrointestinal DiseasesGastrointestinal HemorrhageComorbidityHumansRisk AssessmentRisk FactorsFibrinolytic Agents

Identifiers

PMID38509244
PMCPMC12812041

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.